Schapowal Andreas, Dobos Gustav, Cramer Holger, Ong Kian Chung, Adler Martin, Zimmermann Andrea, Brandes-Schramm Juliette, Lehmacher Walter
Allergy Clinic, Hochwangstraβe 3, 7302 Landquart, Switzerland.
Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen, Am Deimelsberg 34a, 45276 Essen, Germany.
Heliyon. 2019 Nov 26;5(11):e02904. doi: 10.1016/j.heliyon.2019.e02904. eCollection 2019 Nov.
The efficacy of preparation EPs 7630 in the common cold (CC) was assessed by performing meta-analyses of randomized, double-blind, placebo-controlled trials. Mean differences (MD) and risk ratios (RR) with their 95% confidence intervals (CI) were computed. Five trials with a total of 833 patients were included. All trials had a treatment period of ten days with visits at days 3, 5, and 10 after baseline and used a ten-symptom Cold Intensity Score (CIS) as the primary outcome. Significant differences favoring EPs 7630 were observed for total CIS reduction (day 5: MD = -2·30; 95%CI = -4·12,-0·49; day 10: MD = -1·16; 95%CI = -2·22,-0·10), proportion of patients with substantial improvement (day 5: RR = 1·73; day 10: RR = 1·06) and complete remission (day 5: RR = 2·52; day 10: RR = 2·13). Subjects treated with EPs 7630 missed fewer days at work, used less paracetamol and had an improved sleep quality. No serious adverse reactions to EPs 7630 were reported. The results support the efficacy of EPs 7630 in adults with CC.
通过对随机、双盲、安慰剂对照试验进行荟萃分析，评估了EPs 7630制剂对普通感冒（CC）的疗效。计算了平均差（MD）和风险比（RR）及其95%置信区间（CI）。纳入了5项试验，共833例患者。所有试验的治疗期均为10天，在基线后第3、5和10天进行访视，并使用10症状感冒强度评分（CIS）作为主要结局。在CIS总分降低方面观察到有利于EPs 7630的显著差异（第5天：MD = -2·30；95%CI = -4·12，-0·49；第10天：MD = -1·16；95%CI = -2·22，-0·10），症状大幅改善的患者比例（第5天：RR = 1·73；第10天：RR = 1·06）和完全缓解率（第5天：RR = 2·52；第10天：RR = 2·13）。接受EPs 7630治疗的受试者缺勤天数更少，对乙酰氨基酚使用量更少，睡眠质量得到改善。未报告对EPs 7630的严重不良反应。结果支持EPs 7630对成人CC的疗效。
